Cargando…

A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron

COVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths. Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains. They are based on the Spike protein of the Wuhan reference virus, which althou...

Descripción completa

Detalles Bibliográficos
Autores principales: Palatnik-de-Sousa, Iam, Wallace, Zachary S., Cavalcante, Stephany Christiny, Ribeiro, Maria Paula Fonseca, Silva, João Antônio Barbosa Martins, Cavalcante, Rafael Ciro, Scheuermann, Richard H., Palatnik-de-Sousa, Clarisa Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537284/
https://www.ncbi.nlm.nih.gov/pubmed/36202985
http://dx.doi.org/10.1038/s41598-022-21207-2
_version_ 1784803166103011328
author Palatnik-de-Sousa, Iam
Wallace, Zachary S.
Cavalcante, Stephany Christiny
Ribeiro, Maria Paula Fonseca
Silva, João Antônio Barbosa Martins
Cavalcante, Rafael Ciro
Scheuermann, Richard H.
Palatnik-de-Sousa, Clarisa Beatriz
author_facet Palatnik-de-Sousa, Iam
Wallace, Zachary S.
Cavalcante, Stephany Christiny
Ribeiro, Maria Paula Fonseca
Silva, João Antônio Barbosa Martins
Cavalcante, Rafael Ciro
Scheuermann, Richard H.
Palatnik-de-Sousa, Clarisa Beatriz
author_sort Palatnik-de-Sousa, Iam
collection PubMed
description COVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths. Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains. They are based on the Spike protein of the Wuhan reference virus, which although highly antigenic suffered many mutations in SARS-CoV-2 variants, escaping vaccine-generated immune responses. Multiepitope vaccines based on 100% conserved epitopes of multiple proteins of all SARS-CoV-2 variants, rather than a single highly mutating antigen, could offer more long-lasting protection. In this study, a multiepitope multivariant vaccine was designed using immunoinformatics and in silico approaches. It is composed of highly promiscuous and strong HLA binding CD4(+) and CD8(+) T cell epitopes of the S, M, N, E, ORF1ab, ORF 6 and ORF8 proteins. Based on the analysis of one genome per WHO clade, the epitopes were 100% conserved among the Wuhan-Hu1, Alpha, Beta, Gamma, Delta, Omicron, Mµ, Zeta, Lambda and R1 variants. An extended epitope-conservancy analysis performed using GISAID metadata of 3,630,666 SARS-CoV-2 genomes of these variants and the additional genomes of the Epsilon, Lota, Theta, Eta, Kappa and GH490 R clades, confirmed the high conservancy of the epitopes. All but one of the CD4 peptides showed a level of conservation greater than 97% among all genomes. All but one of the CD8 epitopes showed a level of conservation greater than 96% among all genomes, with the vast majority greater than 99%. A multiepitope and multivariant recombinant vaccine was designed and it was stable, mildly hydrophobic and non-toxic. The vaccine has good molecular docking with TLR4 and promoted, without adjuvant, strong B and Th1 memory immune responses and secretion of high levels of IL-2, IFN-γ, lower levels of IL-12, TGF-β and IL-10, and no IL-6. Experimental in vivo studies should validate the vaccine’s further use as preventive tool with cross-protective properties.
format Online
Article
Text
id pubmed-9537284
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-95372842022-10-08 A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron Palatnik-de-Sousa, Iam Wallace, Zachary S. Cavalcante, Stephany Christiny Ribeiro, Maria Paula Fonseca Silva, João Antônio Barbosa Martins Cavalcante, Rafael Ciro Scheuermann, Richard H. Palatnik-de-Sousa, Clarisa Beatriz Sci Rep Article COVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths. Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains. They are based on the Spike protein of the Wuhan reference virus, which although highly antigenic suffered many mutations in SARS-CoV-2 variants, escaping vaccine-generated immune responses. Multiepitope vaccines based on 100% conserved epitopes of multiple proteins of all SARS-CoV-2 variants, rather than a single highly mutating antigen, could offer more long-lasting protection. In this study, a multiepitope multivariant vaccine was designed using immunoinformatics and in silico approaches. It is composed of highly promiscuous and strong HLA binding CD4(+) and CD8(+) T cell epitopes of the S, M, N, E, ORF1ab, ORF 6 and ORF8 proteins. Based on the analysis of one genome per WHO clade, the epitopes were 100% conserved among the Wuhan-Hu1, Alpha, Beta, Gamma, Delta, Omicron, Mµ, Zeta, Lambda and R1 variants. An extended epitope-conservancy analysis performed using GISAID metadata of 3,630,666 SARS-CoV-2 genomes of these variants and the additional genomes of the Epsilon, Lota, Theta, Eta, Kappa and GH490 R clades, confirmed the high conservancy of the epitopes. All but one of the CD4 peptides showed a level of conservation greater than 97% among all genomes. All but one of the CD8 epitopes showed a level of conservation greater than 96% among all genomes, with the vast majority greater than 99%. A multiepitope and multivariant recombinant vaccine was designed and it was stable, mildly hydrophobic and non-toxic. The vaccine has good molecular docking with TLR4 and promoted, without adjuvant, strong B and Th1 memory immune responses and secretion of high levels of IL-2, IFN-γ, lower levels of IL-12, TGF-β and IL-10, and no IL-6. Experimental in vivo studies should validate the vaccine’s further use as preventive tool with cross-protective properties. Nature Publishing Group UK 2022-10-06 /pmc/articles/PMC9537284/ /pubmed/36202985 http://dx.doi.org/10.1038/s41598-022-21207-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Palatnik-de-Sousa, Iam
Wallace, Zachary S.
Cavalcante, Stephany Christiny
Ribeiro, Maria Paula Fonseca
Silva, João Antônio Barbosa Martins
Cavalcante, Rafael Ciro
Scheuermann, Richard H.
Palatnik-de-Sousa, Clarisa Beatriz
A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron
title A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron
title_full A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron
title_fullStr A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron
title_full_unstemmed A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron
title_short A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron
title_sort novel vaccine based on sars-cov-2 cd4(+) and cd8(+) t cell conserved epitopes from variants alpha to omicron
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537284/
https://www.ncbi.nlm.nih.gov/pubmed/36202985
http://dx.doi.org/10.1038/s41598-022-21207-2
work_keys_str_mv AT palatnikdesousaiam anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT wallacezacharys anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT cavalcantestephanychristiny anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT ribeiromariapaulafonseca anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT silvajoaoantoniobarbosamartins anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT cavalcanterafaelciro anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT scheuermannrichardh anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT palatnikdesousaclarisabeatriz anovelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT palatnikdesousaiam novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT wallacezacharys novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT cavalcantestephanychristiny novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT ribeiromariapaulafonseca novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT silvajoaoantoniobarbosamartins novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT cavalcanterafaelciro novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT scheuermannrichardh novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron
AT palatnikdesousaclarisabeatriz novelvaccinebasedonsarscov2cd4andcd8tcellconservedepitopesfromvariantsalphatoomicron